Journals / Medicine Science / 2017 / Cilt: 6 - Sayı: 2

The value of indirect serum markers in predicting severity of fibrosis in treatment naive patients with non-cirrhotic hepatitis C virus infection

Pages
189–194
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Overall, 78 (98.7%) male and only 1 (1.3%) female patients with a mean age of 24.27±6.08 years were included in the study.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:We conducted this study for determining the value of indirect serum markers such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), INR (International Normalized Ratio) and platelet counts and the roles of the scores such as AST-to-ALT ratio (AAR), AST-to-platelet ratio index (APRI), FIB-4 index, King’s score, Goteborg University Cirrhosis Index (GUCI) and FibroQ in predicting severity of fibrosis in treatment naive patients with non-cirrhotic hepatitis C virus (HCV) infection.
📊
Key Findings & Data:Treatment naive non-cirrhotic chronic HCV patients who underwent percutaneous liver biopsy between 01 January 2012 and 01 June 2015 were included in the study.
💡
Conclusion & Impact:Overall, 78 (98.7%) male and only 1 (1.3%) female patients with a mean age of 24.27±6.08 years were included in the study.
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

We conducted this study for determining the value of indirect serum markers such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), INR (International Normalized Ratio) and platelet counts and the roles of the scores such as AST-to-ALT ratio (AAR), AST-to-platelet ratio index (APRI), FIB-4 index, King’s score, Goteborg University Cirrhosis Index (GUCI) and FibroQ in predicting severity of fibrosis in treatment naive patients with non-cirrhotic hepatitis C virus (HCV) infection. Treatment naive non-cirrhotic chronic HCV patients who underwent percutaneous liver biopsy between 01 January 2012 and 01 June 2015 were included in the study. For evaluating the difference in variables, patients were divided into 2 groups such as no or minimal fibrosis group (fibrosis score<2) and significiant fibrosis group (fibrosis score≥2). Statistical analyses were performed by SSPS 15.0. Overall, 78 (98.7%) male and only 1 (1.3%) female patients with a mean age of 24.27±6.08 years were included in the study. Mean age was 24.27±6.08 years. There was no difference in age variable (p=0.054), platelet counts (p=0.798), INR values (p=0.672), AAR (p=0.522) and FibroQ (p=0.535) between significiant fibrosis group and no or minimal fibrosis group. We found that as a predictor of significiant fibrosis, area under ROC curve (AUROC) for APRI was 0.727 (p=0.001), for FIB-4 index was 0.722 (p=0.001), for King’s score was 0.753 (p<0.001) and for GUCI was 0.720 (p=0.001). Consequently, although they do not substitute liver biopsy, APRI, FIB-4 index, GUCI or King’s score can be used as screening tests to predict significiant fibrosis in treatment naive patients with HCV infection

🔖

Cite This Article

AFYON, M., ARTUK, C., YENİLMEZ, E., ŞİMŞEK, B., KAYA, A. (2017). The value of indirect serum markers in predicting severity of fibrosis in treatment naive patients with non-cirrhotic hepatitis C virus infection. Medicine Science, Cilt: 6 - Sayı: 2, 189–194. https://ajindex.com/articles/277884

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Petta S, Craxi A. Current and future HCV therapy: do we still need other anti-HCV drugs? Liver Int. 2015;35(1):4–10
  2. Yenilmez E, Afyon M, Ulcay A, Ulus S, Kaya A, Erdem H. Evaluation of 135 liver biopsy results between 2011 and 2014, according to hepatitis B virus DNA and liver transaminase levels in naive young patients with HBeAg positive and negative chronic hepatitis B infection. Journal of Clinical Virology. 2015;69:235
  3. Kose S, Ersan G, Tatar B, Adar P, Sengel BE. Evaluation of Percutaneous Liver Biopsy Complications in Patients with Chronic Viral Hepatitis. Eurasian J Med. 2015;47(3):161-4
  4. Afyon M, Artuk C. Noninvasive indirect serum markers of liver fibrosis in patients with chronic viral hepatitis. Turk J Gastroenterol. 2016;27(4):397-8
  5. Stasi C, Milani S. Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness. World J Gastroenterol. 2016;22(4):1711-20
  6. Abdollahi M, Pouri A, Ghojazadeh M, Estakhri R, Somi M. Noninvasive serum fibrosis markers: A study in chronic hepatitis. Bioimpacts. 2015;5(1):17-23
  7. Vergara M, Bejarano G, Dalmau B, Gil M, Miquel M, SanchezDelgado J, Casas M, Puig J, Martinez-Bauer E, Dosal A, Lopez M, Moreno L, Valero O, Bella MR, Calvet X. Usefulness of indirect noninvasive methods in predicting progression to cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol. 2015;27(7):826-33
  8. Schmid P, Bregenzer A, Huber M, Rauch A, Jochum W, Müllhaupt B, Vernazza P, Opravil M, Weber R; Swiss HIV Cohort Study. Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy. PLoS One. 2015;10(9):e0138838
  9. Karagoz E, Ulcay A, Tanoglu A, Kara M, Turhan V, Erdem H, Oncul O, Gorenek L. Clinical usefulness of mean platelet volume and red blood cell distribution width to platelet ratio for predicting the severity of hepatic fibrosis in chronic hepatitis B virus patients. Eur J Gastroenterol Hepatol. 2014;26(12):1320-4
  10. Eminler AT, Ayyildiz T, Irak K, Kiyici M, Gurel S, Dolar E, Gulten M, Nak SG. AST/ALT ratio is not useful in predicting the degree of fibrosis in chronic viral hepatitis patients. Eur J Gastroenterol Hepatol. 2015;27(12):1361-6
  11. Ceylan B, Mete B, Fincanci M, Aslan T, Akkoyunlu Y, Ozguneş N, Colak O, Gunduz A, Senates E, Ozaras R, Inci A, Tabak F. A new model using platelet indices to predict liver fibrosis in patients with chronic hepatitis B infection. Wien Klin Wochenschr.